Evidence map›Paper›PMID 35260169›Full record

ArticleBMC medicine2022

Naturally acquired antibody kinetics against Plasmodium vivax antigens in people from a low malaria transmission region in western Thailand.

Zoe Shih-Jung Liu, Jetsumon Sattabongkot, Michael White, Sadudee Chotirat, Chalermpon Kumpitak, Eizo Takashima, Matthias Harbers, Wai-Hong Tham, Julie Healer, Chetan E Chitnis and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Naturally acquired antibodies toFrontiers in immunology · 2026
    Article
  7. Article
  8. Immunogenicity ofFrontiers in cellular and infection microbiology · 2025
    Article
  9. Review
  10. Article
  11. Life (Basel, Switzerland) · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Assessment of IgG3 as a serological exposure marker forFrontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Zoe Shih-Jung LiuThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.
Jetsumon SattabongkotMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Michael WhiteInfectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Paris, France.
Sadudee ChotiratMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Chalermpon KumpitakMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Eizo TakashimaProteo-Science Center, Ehime University, Matsuyama, Japan.
Matthias HarbersCellFree Sciences Co., Ltd., Yokohama, Japan and RIKEN Centre for Integrative Medical Sciences, Yokohama, Japan.
Wai-Hong ThamThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.
Julie HealerThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.
Chetan E ChitnisMalaria Parasite Biology and Vaccines, Department of Parasites & Insect Vectors, Institut Pasteur, Paris, France.
Takafumi TsuboiProteo-Science Center, Ehime University, Matsuyama, Japan.
Ivo Mueller *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.
Rhea J Longley *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia. Longley.r@wehi.edu.au.
University of Melbourne · AUMahidol University · THEhime University · JPInstitut Pasteur · FRCellFree Sciences (Japan) · JP

Funding

Discovery & validation of novel P. vivax antigens for identification and monitoriR01AI104822 · NIAID · MAHIDOL UNIVERSITY · PI PRACHUMSRI, JETSUMON · 2013 to 2017
$672k
NIAID NIH HHS R01 AI104822Wellcome Trust 208693/Z/17/Z
6 · The paper itself

Abstract

backgroundPlasmodium vivax (P. vivax) is the dominant Plasmodium spp. causing the disease malaria in low-transmission regions outside of Africa. These regions often feature high proportions of asymptomatic patients with sub-microscopic parasitaemia and relapses. Naturally acquired antibody responses are induced after Plasmodium infection, providing partial protection against high parasitaemia and clinical episodes. However, previous work has failed to address the presence and maintenance of such antibody responses to P. vivax particularly in low-transmission regions.

methodsWe followed 34 patients in western Thailand after symptomatic P. vivax infections to monitor antibody kinetics over 9 months, during which no recurrent infections occurred. We assessed total IgG, IgG subclass and IgM levels to up to 52 P. vivax proteins every 2-4 weeks using a multiplexed Luminex® assay and identified protein-specific variation in antibody longevity. Mathematical modelling was used to generate the estimated half-life of antibodies, long-, and short-lived antibody-secreting cells.

resultsGenerally, an increase in antibody level was observed within 1-week post symptomatic infection, followed by an exponential decay of different rates. We observed mostly IgG1 dominance and IgG3 sub-dominance in this population. IgM responses followed similar kinetic patterns to IgG, with some proteins unexpectedly inducing long-lived IgM responses. We also monitored antibody responses against 27 IgG-immunogenic antigens in 30 asymptomatic individuals from a similar region. Our results demonstrate that most antigens induced robust and long-lived total IgG responses following asymptomatic infections in the absence of (detected) boosting infections.

conclusionsOur work provides new insights into the development and maintenance of naturally acquired immunity to P. vivax and will guide the potential use of serology to indicate immune status and/or identify populations at risk.

Indexed as

MalariaMalaria, VivaxAntibodies, ProtozoanAntigens, ProtozoanHumansKineticsPlasmodium vivaxProtozoan ProteinsThailandAntibodies, ProtozoanAntigens, ProtozoanProtozoan Proteins

Identifiers

PMID35260169
PMCPMC8904165
OpenAlexW4220928060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.